AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development

Integrating genomic, transcriptomic, and immune profiling from tumor samples is being prioritized to inform therapeutic decision-making across diverse cancers. A new multi-year initiative will use an AI platform to integrate next-generation sequencing and immune profiling across more than 20 cancer types.

BostonGene (Waltham, MA, USA) has expanded its strategic research collaboration with Hokkaido University to apply the BostonGene AI-powered platform in translational oncology. The multi-year collaboration aims to generate actionable, high-quality data to support development of precision therapies for patients in Japan. The partnership centers on producing clinically relevant insights that can be used to guide therapeutic choices.

Under the collaboration, the team will conduct next-generation sequencing and integrate DNA, RNA, and immune system profiling using the proprietary AI platform. The system analyzes genomic and immune profiles from tumor samples, with the goal of identifying patient-specific disease drivers and characterizing underlying immune signatures. These analyses are intended to guide optimal therapeutic decision-making across more than 20 cancer types by aligning molecular and immune features with potential treatment strategies.

The platform is built on a foundation model of tumor and immune biology and integrates multimodal inputs, including genomic, transcriptomic, immune, and clinical signals, to produce biologically grounded intelligence. Within the collaboration, this approach is designed to support patient selection and inform trial design while contributing data that can accelerate precision therapy development. BostonGene Japan, a Tokyo-based joint venture formed by BostonGene, NEC Corporation, and Japan Industrial Partners, is supporting efforts to advance personalized medicine in the country.

“This partnership exemplifies how BostonGene’s AI-driven insights translate complex patient data into meaningful advances in drug development and clinical care, while reinforcing our commitment to advancing translational oncology in Japan, where there is significant and urgent clinical need,” said Yukimasa Shiotsu, President and Representative Director of BostonGene Japan.

Related Links
BostonGene